Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTI-085
- Development stage
- Preclinical
- Lead developer
- InMed Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CTI-085 is an experimental cannabinoid-based ophthalmic therapy being developed as a topical formulation for the treatment of glaucoma. It consists of a proprietary combination of cannabinoids and non–cannabis-derived active ingredients, with the aim of lowering intraocular pressure and providing neuroprotective and anti-inflammatory benefits in the eye.[1][3][9] The program leverages InMed Pharmaceuticals’ cannabinoid drug design and a nanoparticle-based delivery system to enhance ocular penetration and controlled release, and is currently in preclinical development with plans for first-in-human evaluation.[9][13]
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on CTI-085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTI-085.